

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
29 March 2001 (29.03.2001)

PCT

(10) International Publication Number
WO 01/21202 A2(51) International Patent Classification⁷: A61K 39/00

(21) International Application Number: PCT/GB00/03660

(22) International Filing Date:
25 September 2000 (25.09.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
9922505.4 24 September 1999 (24.09.1999) GB

(71) Applicant (for all designated States except US): THE MATHILDA AND TERENCE KENNEDY INSTITUTE OF RHEUMATOLOGY [GB/GB]; 1 Aspenlea Road, Hammersmith, London W6 8LH (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BRENNAN, Fionula, Mary [AU/GB]; The Mathilda and Terence Kennedy Institute of Rheu, matology, 1 Aspenlea Road, Hammersmith, London W6 8LH (GB). FELDMANN, Marc [AU/GB]; The Mathilda and Terence Kennedy Institute of Rheu, matology, 1 Aspenlea Road, Hammersmith, London W6 8LH (GB). FOXWELL, Brian, Maurice, John [GB/GB]; The Mathilda and Terence Kennedy Institute of Rheu, matology, 1 Aspenlea Road, Hammersmith, London W6 8LH (GB).


(74) Agent: BASSETT, Richard, S.; Eric Potter Clarkson, Park View House, 58 The Ropewalk, Nottingham NG1 5DD (GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,


[Continued on next page]

(54) Title: THERAPEUTIC METHODS AND COMPOUNDS

A



B



(57) Abstract: The invention provides a method of treatment of a chronic inflammatory disease (such as rheumatoid arthritis) in a patient, the method comprising the administration to the patient of a compound that selectively inhibits T_{ck} cells. Preferably, said compound selectively inhibits T_{ck} cell-induced release of one or more pro-inflammatory cytokines from monocytes. Advantageously, said compound inhibits NF- κ B. Conveniently, said compound activates PI3 kinase. The invention further provides a method of identifying a compound with efficacy in the treatment of a chronic inflammatory disease comprising the step of testing said compound for an ability to selectively inhibit T_{ck} cells. Preferably, said method of identifying a compound with efficacy in the treatment of a chronic inflammatory disease comprises the step of testing said compound for an ability to selectively inhibit T_{ck} cell-induced release of one or more pro-inflammatory cytokines from monocytes. Conveniently, the pro-inflammatory cytokine is tumour necrosis factor α (TNF α). The invention further provides compounds identifiable or identified by said methods and the use of said compounds in medicine. Additionally, the invention provides an antibody-like molecule with specificity for T_{ck} cells, and compounds comprising said antibody-like molecule and a cytotoxic moiety.

WO 01/21202 A2



HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) **Designated States (regional):** ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— *Without international search report and to be republished upon receipt of that report.*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.